Scientific Background and Reference Sources
Becerra-Munoz, V. M., Gomez-Doblas, J. J., Porras-Martin, C., Such-Martinez, M., Crespo-Leiro, M. G., Barriales-Villa, R., Cabrera-Bueno, F. (2018). The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome. Orphanet J Rare Dis, 13(1), 16. doi:10.1186/s13023-017-0754-6
Bin Mahmood, S. U., Velasquez, C. A., Zafar, M. A., Saeyeldin, A. A., Brownstein, A. J., Ziganshin, B. A., Mukherjee, S. K. (2017). Medical management of aortic disease in Marfan syndrome. Ann Cardiothorac Surg, 6(6), 654-661. doi:10.21037/acs.2017.11.09
Dale, M., Fitzgerald, M. P., Liu, Z., Meisinger, T., Karpisek, A., Purcell, L. N., . . . Xiong, W. (2017). Premature aortic smooth muscle cell differentiation contributes to matrix dysregulation in Marfan Syndrome. PLoS One, 12(10), e0186603. doi:10.1371/journal.pone.0186603
Davis, M. R., & Summers, K. M. (2012). Structure and function of the mammalian fibrillin gene family: implications for human connective tissue diseases. Mol Genet Metab, 107(4), 635-647. doi:10.1016/j.ymgme.2012.07.023
Dietz, H. (2017). Marfan Syndrome. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), GeneReviews((R)). Seattle (WA): University of Washington, SeattleUniversity of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. Retrieved from http://dx.doi.org/.
Dietz, H. C., Loeys, B., Carta, L., & Ramirez, F. (2005). Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet, 139c(1), 4-9. doi:10.1002/ajmg.c.30068
Faivre, L., Collod-Beroud, G., Loeys, B., Child, A., Binquet, C., Gautier, E., Boileau, C. (2007). Effect of Mutation Type and Location on Clinical Outcome in 1,013 Probands with Marfan Syndrome or Related Phenotypes and FBN1 Mutations: An International Study. Am J Hum Genet, 81(3), 454-466.
Grewal, N., & Gittenberger-de Groot, A. C. (2018). Pathogenesis of aortic wall complications in Marfan syndrome. Cardiovasc Pathol, 33, 62-69. doi:10.1016/j.carpath.2018.01.005
Hilhorst-Hofstee, Y., Rijlaarsdam, M. E., Scholte, A. J., Swart-van den Berg, M., Versteegh, M. I., van der Schoot-van Velzen, I., . . . Pals, G. (2010). The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family. Hum Mutat, 31(12), E1915-1927. doi:10.1002/humu.21372
Hiratzka, L. F., Bakris, G. L., Beckman, J. A., Bersin, R. M., Carr, V. F., Casey, D. E., Jr., . . . Williams, D. M. (2010). 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation, 121(13), e266-369. doi:10.1161/CIR.0b013e3181d4739e
Jensen, S. A., & Handford, P. A. (2016). New insights into the structure, assembly and biological roles of 10-12 nm connective tissue microfibrils from fibrillin-1 studies. Biochem J, 473(7), 827-838. doi:10.1042/bj20151108
Judge, D. P., & Dietz, H. C. (2005). Marfan's syndrome. Lancet, 366(9501), 1965-1976. doi:10.1016/s0140-6736(05)67789-6
Koo, H. K., Lawrence, K. A., & Musini, V. M. (2017). Beta-blockers for preventing aortic dissection in Marfan syndrome. Cochrane Database Syst Rev, 11, Cd011103. doi:10.1002/14651858.CD011103.pub2
Loeys, B., De Backer, J., Van Acker, P., Wettinck, K., Pals, G., Nuytinck, L., De Paepe, A. (2004). Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat, 24(2), 140-146. doi:10.1002/humu.20070
Milewicz, D. M., Michael, K., Fisher, N., Coselli, J. S., Markello, T., & Biddinger, A. (1996). Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation, 94(11), 2708-2711.
Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., . . . Dietz, H. C. (2003). Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet, 33(3), 407-411. doi:10.1038/ng1116
Pyeritz, R. E. (2017). Etiology and pathogenesis of the Marfan syndrome: current understanding. Ann Cardiothorac Surg, 6(6), 595-598. doi:10.21037/acs.2017.10.04
Radke, R. M., & Baumgartner, H. (2014). Diagnosis and treatment of Marfan syndrome: an update. Heart, 100(17), 1382-1391. doi:10.1136/heartjnl-2013-304709
Schrijver, I., Liu, W., Brenn, T., Furthmayr, H., & Francke, U. (1999). Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet, 65(4), 1007-1020. doi:10.1086/302582
Sellers, S. L., Milad, N., Chan, R., Mielnik, M., Jermilova, U., Huang, P. L., Bernatchez, P. (2018). Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function. Am J Pathol, 188(3), 574-585. doi:10.1016/j.ajpath.2017.11.006
Whiteman, P., & Handford, P. A. (2003). Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders. Hum Mol Genet, 12(7), 727-737.
Wright, M., & Connolly, H. (2018). Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders - UpToDate. In H. Dietz (Ed.), UpToDate. Retrieved from https://www.uptodate.com/contents/genetics-clinical-features-and-diagnosis-of-marfan-syndrome-and-related-disorders?search=marfan&source=search_result&selectedTitle=1~125&usage_type=default&display_rank=1#H559172.